{
    "clinical_study": {
        "@rank": "168202", 
        "arm_group": [
            {
                "arm_group_label": "ECT", 
                "arm_group_type": "Active Comparator", 
                "description": "Electroconvulsive Therapy Anesthesia and concomitant muscular paralysis"
            }, 
            {
                "arm_group_label": "SHAM ECT", 
                "arm_group_type": "Sham Comparator", 
                "description": "Anesthesia and concomitant muscular paralysis"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine whether addition of electroconvulsive therapy to\n      antipsychotic treatment improves the mental health of patients with treatment-resistant\n      schizophrenia."
        }, 
        "brief_title": "Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Treatment-refractory Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  An ICD-10 schizophrenia diagnosis F20.0-20.3 or F20.9\n\n          -  PANSS total score >= 70\n\n          -  CGI-S >= 4 (Clinical Global Impression)\n\n          -  PANSS score >= 4 on minimum 2 og the following items: Delusions, Conceptual\n             disorganization,Hallucinatory behavior, Excitement, Grandiosity, Suspiciousness,\n             Hostility, Disorientation.\n\n          -  Previous/current treated with clozapine or refused clozapine treatment\n\n          -  Lack of response to at least three different antipsychotics\n\n          -  New antipsychotic medication prescribed more than 8 weeks before inclusion\n\n          -  Fixed dosage of antipsychotics 1 month before inclusion\n\n          -  No chance of additional neurotropic 4 weeks before inclusion\n\n          -  Signed informed consent and power of attorney\n\n        Exclusion Criteria:\n\n          -  Significant substance abuse\n\n          -  Somatic disease that increases the risk of complications of ECT/anesthesia\n\n          -  Epilepsy\n\n          -  For women: Pregnancy or breast-feeding\n\n          -  Homelessness\n\n          -  Use of benzodiazepines (apart from tbl. oxazepam 10 mg., max 30 mg. daily)\n\n          -  Use of antiepileptic\n\n          -  Previous no effect on psychotic symptoms after ECT treatment (minimum 15 ECT-\n             treatments)\n\n          -  Concrete suicidal plans"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948999", 
            "org_study_id": "N-20100085"
        }, 
        "intervention": [
            {
                "arm_group_label": "ECT", 
                "intervention_name": "ECT", 
                "intervention_type": "Procedure", 
                "other_name": "Eletroconvulsive Therapy inclusive anesthesia and concomitan muscular paralysis"
            }, 
            {
                "arm_group_label": "SHAM ECT", 
                "intervention_name": "SHAM ECT", 
                "intervention_type": "Procedure", 
                "other_name": "Anesthesia and concomitan muscular paralysis"
            }, 
            {
                "arm_group_label": [
                    "ECT", 
                    "SHAM ECT"
                ], 
                "intervention_name": "Anesthesia", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Anesthetics"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "electroconvulsive therapy", 
            "treatment-refractory schizophrenia", 
            "electroconvulsive therapy in treatment-refractory schizophrenia"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "email": "jin@rn.dk", 
                "last_name": "Jimmi Nielsen, M.D.", 
                "phone": "+4525779926"
            }, 
            "contact_backup": {
                "email": "besn@rn.dk", 
                "last_name": "Benjamin Sneider, M.D", 
                "phone": "+4530339298"
            }, 
            "facility": {
                "address": {
                    "city": "Aalborg", 
                    "country": "Denmark", 
                    "zip": "9220"
                }, 
                "name": "Aalborg University Hospital, Aalborg Psychiatric Hospital, Centre for Schizophrenia"
            }, 
            "investigator": {
                "last_name": "Jimmi Nielsen, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study", 
        "overall_contact": {
            "email": "jin@rn.dk", 
            "last_name": "Jimmi Nielsen, M.D.", 
            "phone": "+4525779926"
        }, 
        "overall_contact_backup": {
            "email": "s.snel@rn.dk", 
            "last_name": "Sonja Snel, M.D.", 
            "phone": "+4597643563"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: The National Committee on Health Research Ethics", 
                "Denmark: Danish Dataprotection Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PANSS = Positive and Negative Syndrome Scale and UKU = The UKU (Udvalg for Kliniske Unders\u00f8gelser) side effect rating scale", 
            "measure": "Reduction in total PANSS score and adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "The primary outcome will be assessed at screening, baseline and after every second week up to 72 weeks depending on the process for the individaul participant."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948999"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Aarhus", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Aarhus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}